ARL2BP

Across TCGA pan-cancer cohorts, ARL2BP Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ARL2BP data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ARL2BP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARL2BP expression acts as an unfavorable survival marker.

LUSC and COAD are the cancer types where ARL2BP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.537	0.732	<.001	16	view →
COAD	OS	Median	All	0.168	0.806	.002	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ARL2BP–LUSC (OS)

Open the LUSC breakdown →